Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention

NCT03613337 is registered in ClinicalTrials.gov with Cui Yimin as lead sponsor.

NCT NCT03613337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03613337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Lead sponsor
Cui Yimin
Phase
Observational
Overall status
Unknown status
Start date
May 1, 2018
Completion date
August 31, 2020
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clopidogrel, coronary heart disease, genetic risk factors, percutaneous coronary intervention, restenosis, smoking status